This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation are forward-looking statements. Any statements contained in this presentation that are not statements of historical facts may be deemed to be forward-looking statements. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). In some cases, you can identify forward-looking statements by terms such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "will," "would" or the negative of those terms, or other comparable terms intended to identify statements about the future. Forward-looking statements include, but are not limited to, statements about unanticipated safety concerns related to the use of our r-SNM System; FDA or other U.S. or foreign regulatory or legal actions or changes affecting us or our industry; intellectual property, product liability or other litigation against us, our third-party manufacturers or other parties on which we rely or litigation against our general industry; any termination or loss of intellectual property rights; any voluntary or mandatory regulated product recalls; adverse developments concerning our manufacturers or suppliers or any future strategic partnerships; introductions and announcements of new technologies by us, any commercialization partners or our competitors, and the timing of these introductions and announcements; announcements of regulatory approval or disapproval of our r-SNM and any future enhancements to our r-SNM System; adverse results from or delays in clinical studies of our r-SNM System; variations in our financial results or those of companies that are perceived to be similar to us; success or failure of competitive products or therapies in the SNM market; changes in the structure of healthcare payment of our r-SNM System; announcements by us or our competitors of significant acquisitions, licenses, strategic partnerships, joint ventures or capital commitments; market conditions in the medical technology industry and issuance of securities analysts' reports or recommendations; rumors and market speculation involving us or other companies in our industry; sales of substantial amounts of our stock by directors, officers or significant stockholders, or the expectation that such sales might occur; general economic, industry and market conditions, including the size and growth, if any, of the market; the expected or potential impact of the novel coronavirus (COVID-19) pandemic, and the related responses of the government, consumers, and the Company, on our business, financial condition and results of operations; additions or departures of key personnel; changes in our capital structure, such as future issuances of securities and the incurrence of additional debt; the results of any future legal proceedings; and the volatility of the trading price of our common stock. Other important factors that could cause actual results, performance or achievements to differ materially from those contemplated in this presentation can be found in Part I, Item 1. Business," "Part I, Item 1A. Risk Factors," and "Part I, Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report on Form 10-K and "Part I, Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Part II, Item 1A. Risk Factors" of our Quarterly Report on Form 10-Q, which are accessible on the SEC’s website at www.sec.gov.

These forward-looking statements are subject to a number of risks, uncertainties and assumptions. We also operate in a very competitive and rapidly changing environment. New risks emerge from time to time and it is not possible for management to predict all risks, nor can the Company assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in, or implied by, any forward-looking statements. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances described in this presentation may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements contained in this presentation. You should not rely upon forward-looking statements as predictions of future events. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the future results, levels of activity, performance, events, circumstances or achievements reflected in the forward-looking statements may never be achieved or occur. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason after the date of this presentation to conform these statements to actual results or to changes in the Company's expectations.

The Company obtained the industry, statistical and market data, including its general expectations, market position and market opportunity, in this presentation from its own internal estimates and research as well as from industry and general publications and research, surveys and studies conducted by third parties. All of the market data used in this presentation involves a number of assumptions and limitations. While the Company believes that the information from these industry publications, surveys and studies is reliable, the industry in which it operates is subject to a high degree of uncertainty and risk due to a variety of important factors.

These and other factors could cause results to differ materially from those expressed in the estimates made by third parties and by the Company. This presentation contains trademarks, trade names and service marks of other companies, which are the property of their respective owners. The Company does not intend its use or display of other parties' trademarks, trade names or service marks to imply, and such use or display should not be construed to imply, a relationship with, or endorsement or sponsorship of the Company by, these other parties.
Axonics Vision and Philosophy

To be the global leader in providing customer-centric solutions to improve the quality of life for adults with urinary and bowel dysfunction

Clarity of Purpose
Thoughtful Innovation
Integrity and Quality
Company Overview

**Large and Significantly Underpenetrated Market**
- In the U.S., 28M women have moderate to severe urinary incontinence¹ and 19M adults have fecal incontinence²
- High unmet clinical need exists due to limitations of drugs and legacy SNM technology (low efficacy, short duration, etc.)
- Market poised to meaningfully expand, driven by AXNX’s innovative therapies and increased patient awareness

**Complete Portfolio of Innovative Incontinence Solutions**
- AXNX initially introduced a rechargeable SNM device. R20™ is small, long-lived (20+ years), MRI compatible – all market firsts
- Completed SNM portfolio with introduction of F15™, a recharge-free system that offers 15+ years of longevity in the body
- Bulkamid®: next-gen SUI bulking hydrogel clinically proven to retain its bulking characteristics/efficacy for up to 7 years

**Strong Clinical Data in FDA Pivotal Studies**
- SNM: 93% therapy responder rate at 24 months; leaks reduced from 5.6 at baseline to 1.0 at 24 months³
- Bulkamid: 77% of women reported that their incontinence was either “dry, much improved or improved” at 12 months⁴
- Strong safety profile, with no unanticipated adverse events reported in either of the studies

**Significant Commercial Footprint**
- U.S. commercial team is comprised of ~415 professionals (sales reps/managers and clinical/therapy/field marketing specialists)
- Committed to providing best-in-class clinician and patient support; team has extensive urology/neuromodulation experience
- Secured agreements with majority of national and regional hospital systems in the U.S.

**Attractive Financial Profile**
- Revenue of $112M in 2020, year 1 of U.S. commercial launch; revenue guidance for 2023 is $362M
- Long-term gross margin profile in mid-70s; significant operating leverage inherent in business model
- Well capitalized, with >$340M of cash; debt-free balance sheet; adjusted EBITDA positive in 2022 and YTD 09/30/23

---

Management Team

Raymond W. Cohen
Chief Executive Officer
40+ years of experience

Kari Keese
Chief Financial Officer
15+ years of experience

Rinda Sama
Chief Operating Officer
20+ years of experience

Karen Noblett, M.D.
Chief Medical Officer
30+ years of experience

John Woock, Ph.D.
EVP, Chief Marketing and Strategy Officer
15+ years of experience

Al Ford
Chief Commercial Officer
30+ years of experience
Sacral Neuromodulation (SNM) Overview
Overactive Bladder and Bowel Dysfunction in Adults

High prevalence with a debilitating impact on quality of life

**Overactive Bladder (OAB)**

Sudden urge to urinate without getting to the bathroom in time – results in urinary urge incontinence (UUI) and/or urinary frequency (UF)

- 19 million women\(^1\) in the U.S. have moderate to severe symptoms of urinary urge incontinence or mixed urinary incontinence (incontinence related to both urgency and stress)

- 19 million adults\(^2\) in the U.S. have symptoms of fecal incontinence (some adults have dual incontinence, which is symptoms of both fecal incontinence and urinary urge incontinence)

- OAB and FI have a significant negative impact on quality of life, mental health, sleep, productivity, and social activities\(^3\)

- 3 million adults in the U.S. are taking oral prescription medications for their OAB symptoms\(^4\)
  - 80%+ of patients prescribed medications discontinue use within 6 months based on unmet treatment expectations, adverse effects, and cost\(^3\)

- SNM is broadly reimbursed\(^5\) by government and private payors

**Fecal Incontinence (FI)**

Inability to control bowel function, including involuntary loss of solid or liquid feces

4. IQVIA.
5. CMS National Coverage Determination (NCD) is established for sacral nerve stimulation.
Sacral Neuromodulation Therapy

SNM therapy has been commercially available in the United States for 25 years and has been clinically proven to provide a safe, effective, durable solution to OAB and FI

Efficacy of SNM therapy:

- Mild electrical pulses targeting the sacral nerves restore normal communication between the brain and the bladder
- Therapy supported by a large compendium of peer-reviewed publications
- Hundreds of thousands of patients have been implanted worldwide

Historic shortcomings of legacy SNM technology (Medtronic InterStim II®):

- Surgically explanted and replaced every 2-5 years due to battery depletion
- Size of implanted device can result in pain and discomfort
- Complicated patient programmer
- Explant required for a full-body MRI scan
Axonics SNM – U.S. Market Opportunity

- **Adults implanted with SNM in 2022**: Axonics 14,000, Medtronic 37,500
- **Adults treated with 3rd line therapy in 2022**: PTNS 20,000, SNM 51,500, Botox 150,000
- **Adults diagnosed with OAB by a physician in 2021**: 3,000,000+
- **Adults treated with 3rd line therapy**: 221,500
- **Axonics SNM market share**: 27%
- **SNM share of 3rd line therapy**: 23%
- **3rd line therapy market penetration**: 7%

Source: Definitive Healthcare claims data and company estimates.
SNM Market is Underpenetrated and Poised to Expand

Key Drivers Accelerating SNM Market Growth

Innovation by Axonics resulting in more patients saying “Yes” to SNM
- ✓ Long-lived miniaturized implants
- ✓ Full-body MRI compatibility
- ✓ Higher efficacy and patient satisfaction rates
- ✓ Simple, easy to use patient accessories
- ✓ Innovation driving increased physician confidence and enthusiasm

Increasing patient awareness
- ✓ SNM historically a “secret” therapy due to incumbent’s monopoly and lack of investment in patient awareness
- ✓ Axonics committed to raising awareness in partnership with implanting physicians
- ✓ Investing in direct to patient marketing programs to help educate patients about their condition and therapy options

SNM Market Expansion

$800 million

2022

$1.6 billion

Next 5 Years

~15% CAGR

1. Based on claims data and Wall Street research.
2. This forward-looking statement is subject to a number of risks, uncertainties and assumptions. Please see disclaimer on slide 2 for more information.
Axonics Introduced Several Market Firsts with the Launch of its *Rechargeable* SNM System

*(first approved by FDA in Nov 2019; fourth-gen system, Axonics R20, was approved in Jan 2023)*

- **Size of Implantable Neurostimulator (INS):** 60% smaller and half the weight vs. legacy technology (InterStim II®)
- **Implant Life:** 20+ years (4x the longevity of InterStim II®); requires recharging only once every 6-10 months for 1 hour
- **Constant Current Stimulation:** consistent and reliable therapy by adjusting output automatically
- **Full-Body MRI Compatible** with 1.5T and 3T scanners
- **Patient Remote Control:** intuitive, easy to use, and recharge-free
Axonics F15 **Recharge-Free System** *(FDA approval in March 2022)*

*Completes Axonics portfolio of best-in-class SNM solutions*

**Longest Lived Truly Recharge-Free SNM System**
- 15+ years of battery life
- Patients do not recharge *any* system components

**The Smallest Recharge-Free System**
- 10cc in size
- Smaller and thinner than competitive device
- Smooth profile for patient comfort

**Simple and Easy**
- Pocket-sized, intuitive patient remote control.
- Delivers constant current stimulation to reduce therapy adjustments
Axonics Has Set a New Benchmark for Years of Longevity in the Body for Recharge-Free Neuromodulation Devices

<table>
<thead>
<tr>
<th>Amplitude (mA)</th>
<th>0.10</th>
<th>0.50</th>
<th>1.00</th>
<th>1.3</th>
<th>1.50</th>
<th>2.00</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>AxonicsF15</strong></td>
<td>25.0</td>
<td>22.4</td>
<td>17.6</td>
<td>14.9</td>
<td>12.1</td>
<td>8.9</td>
</tr>
<tr>
<td><strong>InterStim X™</strong></td>
<td>16.1</td>
<td>12.3</td>
<td>10.2</td>
<td>-</td>
<td>8.7</td>
<td>7.6</td>
</tr>
</tbody>
</table>

Significantly longer life in the body than InterStim X™

*Based on stimulation amplitude from ARTISAN-SNM patients. Battery life from InterStim X™ System specifications Manual M988757A016 Rev B. Default stimulation settings for both Axonics and Medtronic are shown at Frequency 14 Hz, Pulse Width 210 μs, single or double electrodes.
Axonics is Committed to Continuous Innovation

Second-generation rechargeable INS extended the time between recharging sessions to once a month (from once every two weeks).  
Approved by the FDA in April 2020.

Third-generation rechargeable INS provided patients the ability to make broader stimulation parameter adjustments at home.  
Approved by the FDA in February 2021.

Fourth-generation rechargeable INS extended the time between recharging sessions to just once every six months and increased device longevity to 20+ years.  
Approved by the FDA in January 2023.

Developed a long-lived, recharge-free INS that utilizes a primary cell battery.  
Approved by the FDA in March 2022.
Axonics PMA Study Had the Highest Therapy Responder Rate Ever Reported in Clinical Literature

93% therapy responders at 2-years post-implant

82% better than 75% improved

Safety at 2-Years

- Strong safety profile
- No serious device-related adverse events
- No unanticipated adverse events

Note: number of patients at baseline was 129 and at 2-years was 121.
Published Clinical Data Has Validated Axonics Therapy’s Efficacy and Patient Satisfaction

<table>
<thead>
<tr>
<th></th>
<th>Axonics</th>
<th>Medtronic InterStim Micro</th>
<th>Medtronic InterStim X</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Clinical data on patient experience</strong></td>
<td>2-year ARTISAN experience</td>
<td>No studies completed</td>
<td>No studies completed</td>
</tr>
<tr>
<td><strong>Therapy success rate</strong></td>
<td>93%</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td><strong>Patient satisfaction with therapy</strong></td>
<td>94%</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td><strong>Patients would undergo therapy again</strong></td>
<td>93%</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td><strong>Acceptability of charging experience</strong></td>
<td>94%</td>
<td>No data</td>
<td>No data</td>
</tr>
<tr>
<td><strong>Charging is “EASY”</strong></td>
<td>91%</td>
<td>No data</td>
<td>No data</td>
</tr>
</tbody>
</table>

InterStim® is a registered trademark of Medtronic, Inc.

Stress Urinary Incontinence in Adult Women

What is Stress Urinary Incontinence?

- SUI is the unintentional passing of urine during activity or exertion, such as during coughing, laughing, or exercise
- SUI is caused by a weakness of the pelvic floor muscles, preventing the urethra from closing fully when sudden pressure is put on the bladder
- SUI afflicts women of all ages, with childbirth as one of the main contributing factors
- 22 million women\(^1\) in the U.S. have moderate to severe symptoms of SUI or mixed urinary incontinence (incontinence related to both stress and urgency)

Bulletamid is a best-in-class urethral bulking hydrogel

✓ Durable cushion volume and shape
✓ Biocompatibility – no immunogenicity
✓ Easy to inject – no migration or leakage\(^2\)
✓ Provides durable SUI relief out to 7 years\(^3\)
✓ Simple, fast, easy-to-learn and perform procedure
✓ Minimally invasive – performed in physician’s office or outpatient facility

Bulkamid – U.S. Market Opportunity

Women treated with SUI intervention in 2022

- Bulkamid: 40,000
- Slings: 100,000
- Other Agents: 50,000
- 40,000

Women diagnosed with SUI by a physician in 2021

- No intervention: 5,450,000

Bulkamid market share: 80%
SUI treatment market share: 33%
SUI intervention market penetration: 3%

Source: Definitive Healthcare claims data and company estimates.
Bulkamid Procedure Overview

❖ Bulkamid is injected into the soft tissue of the urethra and adds volume to support the closing mechanism of the urethra, preventing urine from leaking out unintentionally during normal daily activities.

❖ The injections are made into 3-4 locations in the urethral wall; the total volume injected is 1.5-2.0 mL.

❖ Urethral bulking does not close the urethra totally; the urethra still opens normally to allow for urination.

❖ The procedure takes around 10-15 minutes and can be performed in a physician’s office or outpatient facility under local anesthesia.
RCT Results: Bulkamid vs. TVT (sling surgery)

In a randomized controlled trial of 224 women, Bulkamid demonstrated strong efficacy and patient satisfaction with no serious complications.

- **Efficacy**
  - Bulkamid: 92% Subjectively cured/improved, 66% Objectively dry
  - TVT: 100% Subjectively cured/improved

- **Serious complications**
  - Bulkamid: 0%
  - TVT: 3% Tape protrusion, 9% Difficulty emptying bladder, 5% Chronic pain
Sales and Marketing Overview
Comprehensive Practice Support with Broad Geographic Coverage

Commercial team comprised of ~440 sales and clinical support professionals

(~415 in U.S. and 25 in Europe/Australia)
Axonics DTC Campaign

**LEAD GENERATION**
- TV, YouTube, Radio
- Facebook, SEO, Paid Search

**LEAD QUALIFYING**
- FindRealRelief.com Landing Page
- Quiz Completion

**CONNECT & ACTIVATE**
- Nurse Call
- Referral to Provider
- Nurturing
Financial Overview

Revenue
- FY22 revenue of $274 million (+52% y/y)
- FY23 revenue guidance\(^1\) of $362 million (+32% y/y)
  - SNM: $288.5 million
  - Bulkamid: $73.5 million

Gross Margin
- FY22 gross margin of 72% vs. 64% in FY21
- YTD 09/30/23 gross margin of 74.7%

Adjusted EBITDA
- YTD 09/30/23 adjusted EBITDA of $33 million

Balance Sheet
- Cash: $345 million; debt-free

---

1. This forward-looking statement is subject to a number of risks, uncertainties and assumptions. Please see disclaimer on slide 2 for more information.
Axonics Investment Thesis

- Bladder/bowel incontinence market is large, underpenetrated and poised to expand
- Axonics incontinence solutions generate high rates of patient and physician satisfaction
- Best-in-class clinical data with demonstrated efficacy, durability, and safety
- Commercial team with significant experience in urology and neuromodulation
- Strong organic growth outlook with attractive margin profile